MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Distinct Blood Leukocytes Expression Profiles of Long Non-coding RNAs and mRNAs in Parkinson’s disease patients

Y. Fan, Z. Xue (Wuhan, China)

Meeting: 2018 International Congress

Abstract Number: 1685

Keywords: Parkinsonism

Session Information

Date: Monday, October 8, 2018

Session Title: Parkinson's Disease: Pathophysiology

Session Time: 1:15pm-2:45pm

Location: Hall 3FG

Objective: The study aims to identify the significant altered long non-coding RNAs (LncRNA) mRNAs expression profiles of blood leukocytes from Parkinson’s disease (PD) patients, which may contribute to find certain LncRNAs as potential diagnosis biomarkers for PD and provide crucial clues for the studies exploring the LncRNA mechanism in the pathogenesis of PD.

Background: Parkinson’s disease (PD) is a high incidence disabling degenerative disease with unclear pathogenesis. Despite intense investigation , the lacking of reliable biomarkers result that the diagnosis of PD have still relied on the experiences of clinical doctors in a remarkable degree since James Parkinson had reported it the first time in 1817. Researches have illuminated that peripheral immune inflammation play a vital role in the pathogenesis of PD. Long noncoding RNA (LncRNA) is involved in the regulation of gene expression at epigenetics, transcriptional and post-transcriptional levels.

Methods: Peripheral blood leucocytes specimens were obtained from 5 clinically established PD patients[1] and 5 age and sex matched healthy controls and LncRNAs and mRNAs expression profiles were detected by microarray simultaneously. In the purpose of verifying the reliability of microarray date, quantitative real-time PCR. (qRT-PCR) of 6 LncRNAs and mRNAs selected randomly was followed. Bioinformatics tools and databases were employed to predict the potential functions of LncRNAs.

Results: Compared with healthy controls, PD patients had 102 upregulated LncRNAs, 28 downregulated LncRNAs, 12 upregulated mRNAs, 37 downregulated mRNAs(fold change≥2,p<0.05). The results of qRT-PCR, HOTAIRM1, AC131056.3, HOTAIRM1_2.1 and lnc-MOK-6:1 were upregulated in PD patients, while NR4A3 and DEFA4 downregulated, were consistent with microarray data. Several GO terms/ KEGG pathway such as immune response, leukocyte mediated immunity, neuroactive ligand-receptor interaction were enriched in gene lists, suggesting a potential correlation with PD.

Conclusions: The study is the first time to shed light on the different leucocytes LncRNAs and mRNAs expression profiles simultaneously of PD patients from Asia. This information will promote further research on the diagnosis biomarkers and pathogenesis of PD.

References: 1. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015; 30(12): 1591-601.

To cite this abstract in AMA style:

Y. Fan, Z. Xue. Distinct Blood Leukocytes Expression Profiles of Long Non-coding RNAs and mRNAs in Parkinson’s disease patients [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/distinct-blood-leukocytes-expression-profiles-of-long-non-coding-rnas-and-mrnas-in-parkinsons-disease-patients/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/distinct-blood-leukocytes-expression-profiles-of-long-non-coding-rnas-and-mrnas-in-parkinsons-disease-patients/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley